Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Immune checkpoint inhibitors have greatly improved the prognoses of diverse advanced malignancies, including gastric and gastroesophageal junction (G/GEJ) cancer. However, the role of anti-programmed cell death protein-1 treatment in the neoadjuvant setting remains unclear. This phase 2 study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Haiping, Yu, Xiongfei, Li, Ning, Kong, Mei, Ma, Zhimin, Zhou, Donghui, Wang, Weibin, Wang, Haohao, Wang, Haiyong, He, Kuifeng, Li, Zhongqi, Lu, Yimin, Zhang, Jing, Zhao, Kui, Zhang, Yafei, Xu, Nong, Li, Ziran, Liu, Ying, Wang, Yan, Wang, Yisen, Teng, Lisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical Trials Monitor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928365/
https://www.ncbi.nlm.nih.gov/pubmed/35296556
http://dx.doi.org/10.1136/jitc-2021-003635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928365/
https://www.ncbi.nlm.nih.gov/pubmed/35296556
http://dx.doi.org/10.1136/jitc-2021-003635

Ejemplares similares